Find Clinical Trials

Back My cancer has not gone away or has come back Cancer progressed on treatment

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter. If you would like help with this search, please contact us at patientsupport@clearityfoundation.org.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, or drug name, category or target

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

III

Recurrent or progressive high grade serous or endometrioid ovarian cancer with BRCA1/2 mutations (>1 prior therapy)

ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

California, Colorado, Georgia, Maine, Michigan, Ohio, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Rucaparib	AG-014699, PF 01367338, CO-338, Rubraca	PARP inhibitor

II

Recurrent ovarian cancer with germline BRCA1/2 mutations

A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer

Florida, New Mexico, Ohio, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
Olaparib	AZD2281, Lynparza	PARP inhibitor
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells

II

Advanced solid tumors with AKT, ARID1A, ATM, CDKN2A, CHEK2, IDH1/2, KRAS, MRE11A, PIK3CA, PTEN, TP53 and other HDR gene mutations

A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors

Connecticut, Massachusetts, Ohio, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
Adavosertib	WEE1 inhibitor AZD1775, MK1775, AZD1775	WEE1 inhibitor
AZD6738		ATR kinase inhibitor
Capivasertib	Akt inhibitor AZD5363	pan-AKT inhibitor
Olaparib	AZD2281, Lynparza	PARP inhibitor

II

Recurrent ovarian cancer

A Phase 1b/2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer

California, Georgia, New York, Oregon, Pennsylvania, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
DPX-Survivac	survivin antigen vaccine DPX-Survivac	Immune response against cancer expressing survivin
Epacadostat	3-dioxygenase Inhibitor INCB024360, Indoleamine-2,3-dioxygenase Inhibitor INCB024360, INCB024360, IDO1 Inhibitor INCB024360	Inhibits IDO to stimulate immune response

II

Advanced solid tumors

An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies

Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, Nebraska, Nevada, New Jersey, New York, Oregon, South Carolina, Tennessee, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors and granulosa cell ovarian cancer (in expansion)

A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
methoxyamine	TRC102	Base excision repair inhibitor
Temozolomide	Temodal, Temodar, Methazolastone	DNA damaging agent

II

Platinum sensitive ovarian cancer with first recurrence in peritoneal cavity

A Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 Vaccines

Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Alpha-DC1 vaccine		Anti-tumor immune response
Celecoxib	Celebrex
Cisplatin	Platosin, Platistin, Platiran, Platinol, Platinex, Platiblastin-S, Platiblastin, Platamine, Placis, Neoplatin, Metaplatin, Lederplatin, Citosin, Citoplatino, Cisplatyl, Briplatin, Blastolem, Abiplatin, Platinol, CDDP, cis-platinum, cis-DDP, CACP	DNA damaging agent

II

Advanced solid tumors with lesion treatable with radiotherapy

Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease

California

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Platinum sensitive recurrent ovarian cancer (> 1 prior therapy)

Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy

Alaska, California, Colorado, Connecticut, Delaware, Florida, Illinois, Indiana, Maryland, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Virginia, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Olaparib	AZD2281, Lynparza	PARP inhibitor

II

Platinum sensitive, recurrent high grade serous or endometrioid ovarian cancer

Part 1: AVANOVA1 - A Phase I Study to Evaluate the Safety and Tolerability of Bevacizumab-niraparib Combination Therapy and Determine the Recommended Phase 2 Dose (RP2D) in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Part 2: AVANOVA2 - A Two-arm, Open-label, Phase II Randomized Study to Evaluate the Efficacy of Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer.

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Niraparib	MK4827, Zejula	PARP inhibitor

II

Advanced high grade serous, clear cell, or endometrioid ovarian cancer

A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Alabama, Georgia, Michigan, Montana, New Hampshire, South Carolina

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
Gemogenovatucel-T	Vigil, bi-shRNA-furin/GMCSF-expressing autologous tumor cell vaccine, bi-shRNA-furin and granulocyte macrophage colony stimulating factor augmented autologous tumor cell vaccine, FANG vaccine	Immune cell stimulator and TGFbeta inhibitor

II

Recurrent or persistent endometrioid/clear cell ovarian cancer

A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid/Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial Adenocarcinoma

Contact Research Staff

Drug(s) in Trial	Other Drug Names	Main Known Action
Tazemetostat	histone methyl transferase EZH2 inhibitor E7438, EPZ6438, E7438	EZH2 histone methyltransferase inhibitor

II

Recurrent or persistent ovarian cancer (tumor amenable to radiation)

Phase II Trial of Concurrent Anti—PD-L1 and SAbR for Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (With Safety lead-in)

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells

II

Advanced solid tumors with POLE, POLD, or BRCA1/2 mutations

A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability

New Jersey

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Recurrent ovarian cancer

Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer

Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
AZD6738		ATR kinase inhibitor
Olaparib	AZD2281, Lynparza	PARP inhibitor

II

Advanced solid tumors with positive MSI or tumors with negative MSI and high TMB

Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors

California, Maryland, Ohio, Oregon, Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Advanced solid tumors with CDK12 alterations

IMPACT: Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations

Michigan

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Recurrent or refractory high grade serous ovarian cancer or carcinosarcoma

Clinical Study to Assess Efficacy and Safety of MDA-TIL (Autologous Expanded Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
MDA-TIL	autologous tumor-infiltrating lymphocytes MDA-TIL	Anti-tumor immune response

II

Recurrent ovarian cancer with high MSI

An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Ipilimumab	Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, MDX-010, Yervoy	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

II

Platinum sensitive epithelial ovarian cancer with disease progression following maintenance treatment with a PARP inhibitor (at least 2 prior platinum therapies)

A Phase II, Randomized, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Massachusetts

Drug(s) in Trial	Other Drug Names	Main Known Action
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells
Berzosertib	VX-970, M6620, VE-822, ATR kinase inhibitor VX-970	ATR kinase inhibitor
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Gemcitabine	Gemzar	Ribonucleotide reductase and DNA synthesis inhibitor
Paclitaxel	TXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, Anzatax	Microtubule stabilizer/mitotic inhibitor

II

Recurrent ovarian cancer

A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling

California, Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

II

Low grade serous ovarian cancer

A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Contact Research Staff

Drug(s) in Trial	Other Drug Names	Main Known Action
Letrozole	Femara	Aromatase inhibitor
Ribociclib	Kisqali, CDK4/6 Inhibitor LEE011, LEE011, Kisqali	CDK4/6 inhibitor

Ib

Advanced FRalpha+ ovarian cancer (inc expansion)

A Phase 1b/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

Massachusetts, Ohio, Oklahoma, Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Mirvetuximab Soravtansine	M9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid Conjugate	ADC: anti-FOLR1 + microtubule destabilizer (DM4)
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

Ib

Advanced solid tumors (inc ovarian expansion)

A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors

Michigan, Missouri, New York, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
BGB-290	PARP inhibitor BGB-290	PARP inhibitor
Temozolomide	Temodal, Temodar, Methazolastone	DNA damaging agent

Ib

Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma

Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary

Oklahoma

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Galunisertib	LY2157299	TGFBR1 antagonist
Paclitaxel	TXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, Anzatax	Microtubule stabilizer/mitotic inhibitor

Ib

Advanced solid tumors (< 5 prior therapies)

Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer

Arizona, California, Florida, Ohio, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Niraparib	MK4827, Zejula	PARP inhibitor
Paclitaxel	TXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, Anzatax	Microtubule stabilizer/mitotic inhibitor
TSR-042	ANB011, anti-PD-1 monoclonal antibody TSR-042	Blocks PD-L1/2 inhibition of T cells

Ib

Platinum sensitive recurrent ovarian cancer (at least 2 prior platinum therapies)

A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors

Arizona, California, Colorado, Florida, Massachusetts, New York, Pennsylvania, Tennessee, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
BGB-290	PARP inhibitor BGB-290	PARP inhibitor
Tislelizumab	anti-PD-1 monoclonal antibody BGB-A317	Blocks PD-L1/2 inhibition of T cells

Ib

Advanced HER2+ solid tumors (inc expansion)

A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid Tumors

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
PRS-343	anti-HER2 monoclonal antibody/anti-CD137 anticalin bispecific fusion protein PRS-343	Immune response against cancer expressing HER2

Ia/Ib

Advanced solid tumors with mutations in ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1/2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC (inc expansion)

Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies

District of Columbia

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Niraparib	MK4827, Zejula	PARP inhibitor

Ia/Ib

Advanced solid tumors (inc ovarian expansion)

A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors

Arizona, California, Connecticut, Michigan, Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
FPA150	anti-B7-H4 monoclonal antibody FPA150	Immune response against cancer expressing B7-H4, blocks B7-H4 inhibition of T cells

I/II

Platinum sensitive recurrent ovarian cancer

A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors (MEDIOLA)

Maryland, Massachusetts, Missouri, Ohio, Pennsylvania, Texas, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Olaparib	AZD2281, Lynparza	PARP inhibitor

I/II

Recurrent or progressive ovarian cancer

Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer

Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
MV-NIS	oncolytic measles virus encoding thyroidal sodium iodide symporter	Induces immune response and tumor cell lysis

I/II

Recurrent, persistent or refractory high grade serous BRCA1/2-mutated ovarian cancer

A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation

New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Olaparib	AZD2281, Lynparza	PARP inhibitor
Tremelimumab	anti-CTLA4 human monoclonal antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab	Blocks CTLA-4 inhibition of T cells

I/II

Advanced solid tumors

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors

Colorado, Florida, Maryland, New Jersey, New York, Oregon, Pennsylvania, South Carolina, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986249	Probody of ipilumumab	Blocks CTLA-4 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid tumors

A Phase 1/2a Study of BMS-986253 in Combination With Nivolumab in Advanced Cancers

Colorado, Maryland, Michigan, Nevada, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, South Carolina, Texas, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
BMS-986253		IL-8 antagonist
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells

I/II

Advanced solid tumors (inc ovarian expansion)

A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

California, Connecticut, New Jersey, New York, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
NC318

I/II

Advanced solid tumors (inc ovarian expansion)

An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Rebastinib	multitargeted tyrosine kinase inhibitor DCC-2036	Multi-targeted kinase inhibitor

I/II

Advanced solid cancers (inc expansion)

Poly-ICLC (Hiltonol®) Plus Anti-PD1 or Anti-PD-L1 in Unresectable Solid Cancers An Adaptive Phase I/II Clinical Pilot Study

Maryland, New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Nivolumab	BMS-936558, ONO-4538, MDX-1106, Anti-PD-1 human mab MDX-1106, Opdivo	Blocks PD-L1/2 inhibition of T cells
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells
poly ICLC	poly I:poly C with poly-1-lysine stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Hiltonol, poly-ICLC	Activates dendritic cells and induces interferon production

I/II

Advanced solid tumors (inc expansion)

A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination With MGA012 (Anti-PD-1 Antibody) in Patients With Advanced Solid Tumors

Michigan, North Carolina, Virginia

Drug(s) in Trial	Other Drug Names	Main Known Action
MGA012	anti-PD-1 monoclonal antibody MGA012, INCMGA00012	Blocks PD-L1 inhibition of T cells
MGC018	A humanized anti-B7-H3 antibody conjugated to the vc- seco - DUocarmycin-hydroxyBenzamide-Azaindole (DUBA) 2 DNA alkylating payload	ADC: anti-B7-H3 + DNA alkylating agent (Duocarmycin)

I/II

Platinum sensitive ovarian cancer with first or second recurrence in peritoneal cavity

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Cisplatin	Platosin, Platistin, Platiran, Platinol, Platinex, Platiblastin-S, Platiblastin, Platamine, Placis, Neoplatin, Metaplatin, Lederplatin, Citosin, Citoplatino, Cisplatyl, Briplatin, Blastolem, Abiplatin, Platinol, CDDP, cis-platinum, cis-DDP, CACP	DNA damaging agent
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells
Rintatolimod	Ampligen, Atvogen	TLR-3 agonist and immune cell stimulator

I/II

Advanced solid tumors (inc expansion)

Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors

Colorado, Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
BGB-A425		Blocks TIM-3 inhibition of T cells
Tislelizumab	anti-PD-1 monoclonal antibody BGB-A317	Blocks PD-L1/2 inhibition of T cells

I

Advanced solid tumors

A Phase I/II Trial of Topotecan With VX970, an ATR Kinase Inhibitor in Small Cell Cancers

Maryland

Drug(s) in Trial	Other Drug Names	Main Known Action
Berzosertib	VX-970, M6620, VE-822, ATR kinase inhibitor VX-970	ATR kinase inhibitor
Topotecan	TOPO, Hycamtin, Hycamptamine	Topoisomerase I inhibitor

I

Recurrent or persistent ovarian cancer (< 4 prior therapies)

Phase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta™ in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

South Carolina

Drug(s) in Trial	Other Drug Names	Main Known Action
Prolanta		Prolactin receptor antagonist

I

MUC16+ recurrent high grade serous ovarian cancer (> 2 prior therapies)

A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

New York

Drug(s) in Trial	Other Drug Names	Main Known Action
4H11-28z/fIL-12/EFGRt-expressing autologous T lymphocytes	4H11-28z/fIL-12/EFGRt+ genetically-modified T cells, autologous MUC16ecto-targeting EGFR-secreting T lymphocytes	Immune response against cancer expressing CA125
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor

I

Advanced solid tumors including those with BRCA mutations

A Phase 1 Study of Talazoparib (BMN 673) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors

New Jersey, Ohio, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Paclitaxel	TXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, Anzatax	Microtubule stabilizer/mitotic inhibitor
Talazoparib	MDV3800, BMN-673, Talazoparib Tosylate	PARP inhibitor

I

Recurrent advanced ovarian cancer (disease only in abdomen/pelvis)

Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2 in Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
FATE-NK100	NKG2C/CD57-expressing adaptive memory natural killer cells FATE-NK100	Anti-tumor immune response

I

Recurrent ovarian cancer

A Phase Ib Study Evaluating the Safety and Tolerability of Durvalumab (MEDI4736) (Anti-PDL1) in Combination With Eribulin in Patients With HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

New York

Drug(s) in Trial	Other Drug Names	Main Known Action
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Eribulin	B1939 mesylate, E7389, ER-086526, Halaven, halichrondrin B analog	Tubulin polymerization inhibitor

I

Recurrent or persistent FRalpha+ high grade serous ovarian cancer

Phase I Clinical Trial of Adoptive Transfer of Autologous Folate Receptor - Alpha Redirected T Cells for Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
Fludarabine	Fludara Oral, 2-F-ara-AMP, Beneflur	DNA synthesis inhibitor
MOv19-BBz CAR T		Immune response against cancer expressing folate receptor

I

Recurrent high grade ovarian cancer

Phase I/Ib Study of Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ Tumor Antigen-Specific T Cells in Combination With Utomilumab (PF-05082566) in Patients With Platinum Resistant Ovarian Cancer

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Cyclophosphamide	Ciclofosfamida, Ciclofosfamide, Claphene, CP monohydrate, CPM, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphanum, Cytophosphane, Mitoxan, Syklofosfamid, Zytoxan, Clafen, Cytoxan, Neosar, Carloxan, Cicloxal, Cycloblastin, Cycloblastine, CYCLO-cell, Cyclostin, Cyclostine, Cytophosphan, Endoxan, Endoxana, Enduxan, Fosfaseron, Genoxal, Ledoxina, Procytox, Sendoxan	DNA damaging agent
IL-21-Primed CD8+ Tumor Antigen-Specific T Cells	adoptively transferred central memory-type CTL targeting ovarian cancer antigens	Immune response against cancer expressing PRAME and/or COL6A3
Utomilumab	PF-05082566	Stimulates 4-1BB (CD137) to increase T cells and immune response

I

Advanced solid tumors

A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients With Advanced Solid Tumors

Georgia, Illinois, Michigan, South Carolina

Drug(s) in Trial	Other Drug Names	Main Known Action
Pevonedistat	NAE inhibitor MLN4924, Nedd8-activating enzyme inhibitor MLN4924	NAE inhibitor

I

Advanced solid tumors

A Phase I Study of the Anti-C5aR, IPH5401, in Combination With the Anti-PD-L1, Durvalumab, in Patients With Selected Advanced Solid Tumors

Tennessee, Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
IPH5401		Blocks C5aR mediated inhibition of T and NK cells

I

Recurrent or refractory epithelial ovarian cancer

A Phase I, Open Label Study Evaluating the Safety and Efficacy of Adoptive Transfer of Autologous NY-ESO-1 CD8-TCR Engineered T Cells and NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC) After a Myeloablative Conditioning Regimen, With Administration of IL-2 in Patients With Recurrent or Treatment Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer

New York

Drug(s) in Trial	Other Drug Names	Main Known Action
NY-ESO-1 CD4-TCR Engineered Hematopoietic Stem Cells (HSC)		Immune response against cancer expressing NY-ESO-1
NY-ESO-1 CD8-TCR Engineered T Cells		Immune response against cancer expressing NY-ESO-1

I

Platinum sensitive ovarian cancer with ≤ 2 prior platinum therapies (inc expansion)

A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer

Arizona, California, Florida, Georgia, Maryland, Missouri, New York, Oklahoma, Tennessee, Virginia, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	RG7446, MPDL3280A, Anti-PD-L1 Monoclonal Antibody MPDL3280A, Tecentriq	Blocks PD-L1 inhibition of T cells
Cobimetinib	Cotellic, GDC-0973, XL518	MEK1 inhibitor
Niraparib	MK4827, Zejula	PARP inhibitor

I

Advanced solid tumors

A Multicenter, Open-Label, Dose Escalation Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor M3814 in Combination With Avelumab With and Without Palliative Radiotherapy in Participants With Selected Advanced Solid Tumors

Florida, Tennessee

Drug(s) in Trial	Other Drug Names	Main Known Action
Avelumab	Anti programmed death ligand 1 monoclonal antibody, Anti-PD-L1, MSB0010718C, Bavencio	Blocks PD-L1 inhibition of T cells
M3814	DNA-PK inhibitor MSC2490484A	DNA-PK inhibitor

I

Advanced solid tumors that are TP53 WT

A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast Cancer

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
ALRN-6924	MDM2/MDMX inhibitor ALRN-6924	MDM2 and MDMX inhibitor
Paclitaxel	TXL, Taxol Konzentrat, Taxol, Praxel, Bristaxol, Asotax, Anzatax	Microtubule stabilizer/mitotic inhibitor